Chemomab Sets Dec 4 Vote on Scipher Merger; Holders Get 32% of Combined Company
CMMB sits 22% above its 52-week low of $0.92 on elevated volume (2.2× avg).
Summary
Chemomab filed the definitive proxy for a December 4, 2026 special meeting on its merger with Scipher, where holders would own about 32% of the combined company before a $30-50 million PIPE cuts that to roughly 26.7%.
Key Events · M&A and Partnerships · CMMB
-
Special Meeting Set for December 4
Shareholders of record on October 29, 2026 will vote on six proposals; closing requires approval of Proposals 1 through 4 (merger, domestication, Nasdaq issuance, directors).
-
Chemomab Holders Keep 32% Pre-PIPE
In a $150 million combined valuation, Chemomab is valued at $48 million and Scipher at $102 million; before the PIPE, Chemomab holders get 32% and Scipher noteholders 68%.
-
PIPE Cuts Chemomab to 26.7%
A $30-50 million PIPE at a $150 million combined valuation with 100% warrant coverage at 50% of valuation leaves Chemomab holders at about 26.7%, Scipher noteholders at 56.7% and PIPE investors at 16.6%.
-
CVRs Pay Up to $50 Million
Holders receive CVRs paying $40 million on a nebokitug PSC Phase 3 start or disposition and $10 million on FDA approval in any indication, within a seven-year term; the CVRs will not be listed or traded.
Analysis · CMMB · Life Sciences
The definitive proxy now puts the Scipher merger to a shareholder vote on December 4, 2026. Before a $30-50 million PIPE that cuts them to about 26.7%, Chemomab holders would keep roughly 32% of the combined company, with Scipher noteholders at 56.7% and PIPE investors at 16.6%. Effectively a referendum on the only funded path forward, the vote comes as Chemomab had about $6.7 million of cash at June 30, 2026 and has said substantial doubt exists about continuing as a going concern absent the merger or new financing. Holders also receive CVRs worth up to $40 million on a nebokitug PSC Phase 3 or disposition and $10 million on any FDA approval, but those are contractual, non-traded rights that may never pay. Approval of Proposals 1 through 4 is required; failure to close leaves Chemomab to raise money alone or consider liquidation.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMMB was trading at $1.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.9M. The 52-week trading range was $0.92 to $3.23. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.